HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial.

ABSTRACT:

Objectives

The HandScan is a novel method to quickly and objectively quantify RA disease activity using optical spectral transmission in hands and wrists. The aim of this study was to investigate whether treat-to-target (T2T) in early RA patients aimed at 'HandScan' remission is non-inferior to that aimed at ACR/EULAR 2011 'Boolean' remission.

Methods

We performed a multicentre randomized double-blind, non-inferiority trial. Newly diagnosed RA patients naive to DMARDs were randomized 1:1 to targeting HandScan remission or Boolean remission. At monthly visits, treatment was intensified/continued/deescalated according to the respective target following a predefined treatment schedule. Primary outcome was the HAQ score at 18 months, and non-inferiority was tested using a non-in

SUBMITTER: van der Leeuw MS 

PROVIDER: S-EPMC12456276 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature